CRA acquires bioStrategies Group, Inc.
Today CRA announced its acquisition of bioStrategies Group, Inc., a Chicago-based consulting firm focused on developing commercial strategies for healthcare...
Chris Schneider is Vice President at CRA and has more than 20 years of broad biopharma experience in a variety of commercial strategy and analytical roles on both the client and the consulting sides of the business. He brings to his engagements more than 10 years of client-side experience at both Roche and Pfizer across the finance, strategic pricing, customer development, and business development functions.
His areas of specialization have been pipeline and pre-launch commercial strategy, new product forecasting, asset/pipeline commercial evaluations, indication prioritization, lifecycle management, and market access/pricing. Chris has managed multi-phase strategy projects across a broad range of therapeutic categories, with particular focus in oncology, hematology, immunology, rare diseases, and endocrinology.
Prior to joining CRA, Chris was Partner of bioStrategies Group, a firm offering research and analysis in support of commercial strategy decisions to life science companies. Previously he worked at Roger Green and Associates and Ipsos.